Isavuconazonium sulfate

DRUG2 trials

Sponsors

Astellas Pharma Global Development, Inc.

Conditions

Invasive AspergillosisInvasive Fungal InfectionInvasive Mucormycosis

Phase 2

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

CompletedNCT03816176

Astellas Pharma Global Development, Inc.Invasive Aspergillosis, Invasive Mucormycosis

Start: 2019-08-22End: 2022-12-14Updated: 2024-12-05

Unknown Phase

Registry of Patients Treated With Systemic Mold-Active Triazoles

CompletedNCT03066011

Astellas Pharma Global Development, Inc.Invasive Fungal Infection

Start: 2017-03-16End: 2020-04-24Updated: 2024-10-21

Related Papers

Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial

Antimicrobial Agents and Chemotherapy2024-11-1414 citations

2537. Population Pharmacokinetics of Isavuconazole in Pediatric Patients

Open Forum Infectious Diseases2023-11-271 citations